Will two technology entrepreneur teams from India bring the Next Big Idea?

The Next Big Idea, a Business Plan Competition, sponsored by Department of Science & Technology, Government of India and Intel in association with Nadathur S Raghavan Centre for Entrepreneurial Learning (NSRCEL), at the Indian Institute of Management Bangalore (IIMB) aims to encourage innovation, create structure and process for the business plan competitions for leading academic institutions across India so that the innovative ideas born through these competitions are taken forward to become real businesses. Next Big Idea also aims to create a platform where any individual or team can post their innovative ideas and seek mentoring, access to incubation and angel funds to help them create a real business.

One more objective of this program is to build capacity in Academic Institutions that conduct business plan competitions thereby helping to improve the quality of business ideas originated from there. The capacity building through Academic Institutions includes offering financial support to their competitions and conducting a two day fully paid conference at IIM Bangalore to enable sharing of information and best practices to conduct competitions.

The incentives to the 40 winning teams include a chance to be incubated and raise seed funding, a one week fully paid workshop at IIM Bangalore with intensive mentoring and an opportunity to interact with VCs, cash prizes and a sponsorship to participate in Intel+Berkeley Technology Entrepreneurship Challenge (IBTEC) for top 2 teams.

The two teams that will be participating at IBTEC next week from the Next Big Idea are iSensor Diagnostics and Brizz TV.

iSensor Diagnostics is a novel Lab-on-Chip device for the measurement of cardiac markers and was founded by Vijaywanth Mathur, iSensor Diagnostics.

iSensor Diagnostics intends to leverage its expertise in Biosensors/ Immuno sensors and micro fluidics to design and develop a world’s first iSensLab- a paradigm shift, point-of-care, self-calibrating, high performance, inexpensive (< $1.00) plastic biochip cartridge for rapid (in minutes) quantitative measurement of low concentration disease markers in whole blood serum samples which, will result in a hand-held device for rapid screening and diagnosis of cardiac, cancer and infectious disease markers.

The proposed method utilizes a novel, inexpensive plastic biochip based electrochemical biosensor-a paradigm shift as compared to silicon chips. The developed technology platform can now be easily adapted for low cost, sensitive and rapid measurement of cancer markers and infectious diseases in low resource settings such as in semi-urban and rural areas in the developing countries.

BrizzTV was founded by Krishnan Varadarajan (Cofounder CTO), Amarendra Sahu (Cofounder CEO), Jitendra Jagadev (Cofounder COO) at the Indian Institute of Management (IIM), Bangalore.

BrizzTV brings personal web content of choice to your living room couches that you can enjoy on TV with a press of a button. Their patent pending digital media platform will serve as the backbone for the world's very first 'DTH (direct to home) TV App Store'. With BrizzTV, access to, affordability of and familiarity with the Internet will no longer holdback people from consuming content available over the web!

In the past Indian teams have made a significant mark at IBTEC. In 2006 team Richcore received a first runner up and in 2008 team Polyskin again received a first runner up. This year with iSensor and BrizzTV the India teams are again aiming for the top honors at IBTEC 2010.

One Response to Will two technology entrepreneur teams from India bring the Next Big Idea?

  1. Randox have already developed this multiplex biochip technology. Randox Biochip Array Technology (BAT) is an innovative assay technology for multi-analyte screening of biological samples in a rapid, accurate and easy to use format. With FDA approval for BAT and Randox’s Drugs of Abuse biochip arrays, users can have confidence in proven analysers, reagents and procedures.
    The multi-analyte approach has benefits beyond time and cost savings, which are vital in the drive towards increasing efficiencies and improved clinical performance. Traditional diagnosis takes the form of single analyte assays, even though several are usually required, thus increasing sample volumes, possibly requiring multiple patient attendance and increasing the time before diagnosis. A multi-analyte assay will reduce patient discomfort, as many related tests can be run at once, negating the need for multiple patient sampling. Multiple markers also give a more comprehensive picture of the patient’s condition, so providing an accurate and rapid diagnosis. This in turn will lead to better patient care.
    Our Cardiac Array utilises cutting-edge biochip array technology to simultaneously measure four cardiac biomarkers and provide results within 30 minutes. It offers a comprehensive biochemical profile of patients presenting to hospital with chest pain and suspected acute coronary syndrome.
    The Cardiac Array can be used with Randox’s rapid testing platform, Evidence MultiStat, which can be placed in the Emergency Department, Cardiology clinic or central Biochemistry laboratory. MultiStat provides highly accurate and precise “near-patient” results that can be fully trusted by consultants and aid the clinical management of patients.